Calliditas Therapeutics Past Earnings Performance
Past criteria checks 0/6
Calliditas Therapeutics's earnings have been declining at an average annual rate of -22.5%, while the Pharmaceuticals industry saw earnings growing at 10.8% annually. Revenues have been growing at an average rate of 59.4% per year.
Key information
-22.5%
Earnings growth rate
-18.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 59.4% |
| Return on equity | -449.8% |
| Net Margin | -30.0% |
| Next Earnings Update | 11 Nov 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Calliditas Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1,601 | -480 | 1,314 | 558 |
| 31 Mar 24 | 1,311 | -525 | 1,163 | 526 |
| 31 Dec 23 | 1,207 | -466 | 1,061 | 502 |
| 30 Sep 23 | 1,184 | -451 | 1,040 | 498 |
| 30 Jun 23 | 1,150 | -292 | 968 | 421 |
| 31 Mar 23 | 944 | -393 | 872 | 428 |
| 31 Dec 22 | 803 | -412 | 775 | 415 |
| 30 Sep 22 | 405 | -628 | 653 | 413 |
| 30 Jun 22 | 343 | -608 | 562 | 402 |
| 31 Mar 22 | 279 | -576 | 474 | 381 |
| 31 Dec 21 | 229 | -500 | 390 | 357 |
| 30 Sep 21 | 199 | -452 | 302 | 331 |
| 30 Jun 21 | 0 | -600 | 248 | 304 |
| 31 Mar 21 | 0 | -501 | 182 | 277 |
| 31 Dec 20 | 1 | -433 | 142 | 241 |
| 30 Sep 20 | 47 | -286 | 102 | 209 |
| 30 Jun 20 | 47 | -198 | 71 | 190 |
| 31 Mar 20 | 185 | -54 | 71 | 173 |
| 31 Dec 19 | 185 | -33 | 63 | 150 |
| 30 Sep 19 | 138 | -54 | 47 | 142 |
| 30 Jun 19 | 138 | -35 | 44 | 120 |
| 31 Mar 19 | 0 | -136 | 33 | 99 |
| 31 Dec 18 | 0 | -132 | 31 | 99 |
| 30 Sep 18 | 0 | -128 | 64 | 65 |
| 30 Jun 18 | 0 | -115 | 74 | 41 |
| 31 Mar 18 | 0 | -113 | 81 | 31 |
| 31 Dec 17 | 0 | -87 | 85 | 0 |
| 31 Dec 16 | 0 | -57 | 56 | 0 |
Quality Earnings: LC8 is currently unprofitable.
Growing Profit Margin: LC8 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LC8 is unprofitable, and losses have increased over the past 5 years at a rate of 22.5% per year.
Accelerating Growth: Unable to compare LC8's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LC8 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: LC8 has a negative Return on Equity (-449.83%), as it is currently unprofitable.